A recent study by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has shown that a combination of the immune checkpoint inhibitor pembrolizumab and chemotherapy may improve survival outcomes for patients with small cell bladder cancer (SCBC) and small cell/neuroendocrine prostate cancer (NEPC). The research, published in Cell Reports…

Men with treatment-emergent neuroendocrine prostate cancer (t-NEPC) could benefit from human epidermal growth factor receptor (HER)2 testing and treatment with trastuzumab deruxtecan (T-DXd), suggest researchers from the Washington DC Veterans Affairs Medical Center and The George Washington University School of Medicine. They report in the Annals of Internal Medicine, the…

Researchers led by CSHL professor Lloyd Trotman’s lab have found that the pro-oxidant supplement menadione slows prostate cancer progression in mice. The supplement is a precursor to vitamin K, commonly found in leafy greens. The findings are published in Science in an article titled, “Dietary pro-oxidant therapy by a vitamin…

A healthy diet may reduce the chance of low risk prostate cancer progressing in men undergoing active surveillance, according to a team led by researchers at Johns Hopkins Medicine. This finding further supports the idea that men with lower risk prostate cancer can be carefully monitored in lieu of undergoing…

Men with a specific prostate cancer mutation could benefit from treatment with dual immunotherapy with immune checkpoint inhibitors. Writing in the Annals of Oncology, Niven Mehra, MD, PhD, an oncologist and researcher based at the Radboud University Medical Center in the Netherlands, and colleagues report that men whose tumor had…

Widespread, opportunistic testing for prostate specific antigen (PSA) could be contributing the overdiagnosis of prostate cancer across Europe, researchers warn. Their findings, in The BMJ, have implications for prostate cancer screening programs and initiatives such as Europe’s Beating Cancer Plan. This EU project recently released recommendations from European Commission’s council…

Data from a team of Australian researchers shows the potential of a new therapeutic strategy for treating castration-resistant prostate cancer (CRPC), the most aggressive form of the disease. The research, published in the British Journal of Cancer, studied the role of Cyclin-Dependent Kinase 9 (CDK9) in the progression of aggressive…

An international study led by the Radboud University Medical Center has demonstrated that artificial intelligence (AI) can detect prostate cancer on MRI scans more effectively than radiologists, while also reducing false positives by half. The findings, published in The Lancet Oncology, mark a significant advancement in the use of AI…

A first-in-man study, by researchers at the Nuffield department of surgical sciences and the department of oncology, at the University of Oxford, Oxford University Hospitals and Oxford NIHR Biomedical Research Center University of Oxford, and at Oxford University Hospitals NHS Trust, demonstrates how a fluorescent marker dye that sticks to…

A City of Hope-developed CAR T cell therapy has shown it is both safe and produced promising therapeutic activity in patients with metastatic castration resistant prostate cancer (mCRPC). Results of the Phase I clinical trial were published today in Nature Medicine. The study treated 14 patients with prostate stem cell…

Applying three-dimensional AI to biopsies could predict the recurrence of prostate cancer better than traditional histopathology, researchers report. Their TriPath 3D pathology deep-learning platform more accurately reflected the intrinsically diverse nature of human tissue and could help guide clinical decisions, according to the findings reported in the journal Cell. The…

Researchers at the University of Michigan Rogel Cancer Center have announced the development of a novel urine-based test named MyProstateScore2.0 (MPS2), aiming to revolutionize the diagnosis of prostate cancer by identifying high-grade cancers that require immediate intervention. Reporting in JAMA Oncology, the new test could significantly decrease the number of…

Researchers from the Brigham and Women’s Hospital, drawing on a range of research studies of prostate cancer, report that a diagnostic approach combining both MRI with prostate-specific antigen (PSA) density can help doctors avoid performing unnecessary prostate biopsies. The results, published last week in JAMA Network Open provides a new…

A U.K. study has shown that prostate cancer can be classified into two distinct prostate cancer subtypes according to how gene mutations evolve within the tumors, with one type linked to more aggressive disease than the other. The discovery was made by an international team, led by the University of…

Researchers from Dana-Farber Cancer Institute and the University of Trento, Italy, report in Cancer Discovery, that they have developed a new blood test differentiates neuroendocrine prostate cancer (NEPC) once it has advanced from adenocarcinoma. Having a non-invasive method to detect this switch has important implications for this hard-to-treat form of…